Sitari Pharmaceuticals

NEWS
Sitari Pharmaceuticals was acquired by GlaxoSmithKline in 2019.
Building on its unique six-year relationship with Avalon Ventures, GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for celiac disease.
IN THE PRESS
AWARDS
  • NextGen Class of 2015